Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.

Wang Y, Chen J, He Y, Lv Y, Guo H, Zheng Q, Li L

Diabetes, obesity & metabolism11 Jul 2025Cited by 2 (Europe PMC)

PMID40642833DOI10.1111/dom.16599PepBankPUB-40642833

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In children and adolescents with obesity, semaglutide had model-adjusted mean weight reduction of 12.55 kg at 56 weeks (95% CI: 10.17-16.19) after placebo-effect removal.
In plain wordsIn pediatric obesity models, semaglutide showed estimated weight reduction; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseBody weight at 56 weeks
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Model-adjusted weight-reduction magnitude
12.55 kg
56-week modeled assessment; placebo effects removed
95% CI
10.17 to 16.19 kg
modeled weight reduction
Source sentences
Summary
with losses of 12.55 (10.17-16.19), 10.16 (8.06-12.30), 5.86 (4.10-7.62), 3.23 (1.11-5.36), 2.66 (2.06-3.28), 2.29 (0.26-4.37), and 1.93 (1.17-2.72) kg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
A comprehensive review of 31 articles involving 1723 participants from public databases was conducted.
Summary · context
To control for study variations, baseline BMI values were standardised to a median of 35.3 kg/m², and placebo effects were removed to accurately determine drug efficacy.
Report a problemFND-4064283301
02HumanSystematic reviewEfficacy outcome
No significant difference in semaglutide effectiveness was found between children/adolescents and adults.
In plain wordsIn obesity-trial models, semaglutide effectiveness showed no significant difference between children/adolescents and adults.
Peptide
Semaglutide
Outcome
No significant changeDrug effectiveness by age group
Study
n: not reported in source
Comparator
Adults
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No significant differences in drug effectiveness were found between children/adolescents and adults for semaglutide, liraglutide, orlistat and high-dose PT (15/92 mg).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
These were then compared with efficacy models for adult patients to investigate differences in drug effectiveness between the two age groups.
Report a problemFND-4064283303
03HumanSystematic reviewEfficacy outcome
No significant difference in liraglutide effectiveness was found between children/adolescents and adults.
In plain wordsIn obesity-trial models, liraglutide effectiveness showed no significant difference between children/adolescents and adults.
Peptide
Liraglutide
Outcome
No significant changeDrug effectiveness by age group
Study
n: not reported in source
Comparator
Adults
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No significant differences in drug effectiveness were found between children/adolescents and adults for semaglutide, liraglutide, orlistat and high-dose PT (15/92 mg).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
These were then compared with efficacy models for adult patients to investigate differences in drug effectiveness between the two age groups.
Report a problemFND-4064283304

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
Across the GLP-1 receptor agonist group including liraglutide, model-adjusted mean weight reduction was 1.93 kg at 56 weeks (95% CI: 1.17-2.72).
In plain wordsIn pediatric obesity models, the GLP-1 group including liraglutide showed estimated weight reduction; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody weight at 56 weeks
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Model-adjusted weight-reduction magnitude
1.93 kg
56-week modeled assessment; placebo effects removed
95% CI
1.17 to 2.72 kg
modeled weight reduction
Source sentences
Summary
with losses of 12.55 (10.17-16.19), 10.16 (8.06-12.30), 5.86 (4.10-7.62), 3.23 (1.11-5.36), 2.66 (2.06-3.28), 2.29 (0.26-4.37), and 1.93 (1.17-2.72) kg, respectively.
5 context sentences(design, population, supporting numbers)
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
A comprehensive review of 31 articles involving 1723 participants from public databases was conducted.
Summary · context
To control for study variations, baseline BMI values were standardised to a median of 35.3 kg/m², and placebo effects were removed to accurately determine drug efficacy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283302
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
Across GLP-1 receptor agonists including liraglutide, subgroup analyses indicated particular effectiveness in patients with non-metabolic obesity.
In plain wordsIn pediatric obesity models, the GLP-1 group including liraglutide was particularly effective in non-metabolic obesity; the exact comparison was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedWeight-loss effectiveness in non-metabolic obesity
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Subgroup analyses indicated that GLP-1 receptor agonists and orlistat were particularly effective in patients with non-metabolic forms of obesity, and drugs were more efficacious in males.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283305
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In modeled obesity-drug trials including liraglutide, the overall drug pool reached efficacy plateaus in 32.9-47.8 weeks; this range was not assigned to the GLP-1 group or native liraglutide alone.
In plain wordsIn obesity-drug models including liraglutide, pooled drugs reached plateaus in 32.9-47.8 weeks; no liraglutide-specific time was reported.
Peptide
Liraglutide
Outcome
Direction not reportedTime to efficacy plateau across modeled drugs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Reported overall plateau-time range
32.9 to 47.8 weeks
all modeled drugs; not assigned to native drug or GLP-1 group
Source sentences
Summary
Drugs took 32.9-47.8 weeks to achieve their efficacy plateau, with GLP-1 receptor agonists acting most rapidly.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283306
07HumanNot a test of Semaglutide aloneSystematic reviewOther
Across obesity-drug models including semaglutide, baseline BMI significantly affected weight-loss outcomes; the signed coefficient, original continuous reference and analyzed subset N were unstated.
In plain wordsIn obesity-drug models including semaglutide, baseline BMI was linked to weight-loss outcomes; the signed association and exact reference were unstated.
Peptide
Semaglutide
Outcome
Direction not reportedBaseline BMI association with modeled weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The analysis demonstrated that baseline Body Mass Index (BMI) significantly affected weight loss outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4064283307
08HumanNot a test of Semaglutide aloneSystematic reviewOther
Across obesity-drug subgroup models including semaglutide, greater efficacy was reported in males; the exact original reference, native estimate and analyzed subset N were unstated.
In plain wordsIn obesity-drug models including semaglutide, male sex was linked to greater reported efficacy; the exact reference and native estimate were unstated.
Peptide
Semaglutide
Outcome
Direction not reportedModeled drug efficacy association with male sex
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Subgroup analyses indicated that GLP-1 receptor agonists and orlistat were particularly effective in patients with non-metabolic forms of obesity, and drugs were more efficacious in males.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4064283308
09HumanNot a test of Liraglutide aloneSystematic reviewOther
Across obesity-drug models including liraglutide, baseline BMI significantly affected weight-loss outcomes; the signed coefficient, original continuous reference and analyzed subset N were unstated.
In plain wordsIn obesity-drug models including liraglutide, baseline BMI was linked to weight-loss outcomes; the signed association and exact reference were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBaseline BMI association with modeled weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The analysis demonstrated that baseline Body Mass Index (BMI) significantly affected weight loss outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283309
10HumanNot a test of Liraglutide aloneSystematic reviewOther
Across obesity-drug subgroup models including liraglutide, greater efficacy was reported in males; the exact original reference, native estimate and analyzed subset N were unstated.
In plain wordsIn obesity-drug models including liraglutide, male sex was linked to greater reported efficacy; the exact reference and native estimate were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedModeled drug efficacy association with male sex
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Subgroup analyses indicated that GLP-1 receptor agonists and orlistat were particularly effective in patients with non-metabolic forms of obesity, and drugs were more efficacious in males.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283310
11HumanNot a test of Semaglutide aloneSystematic reviewOther
In modeled obesity-drug trials including semaglutide, the overall drug pool reached efficacy plateaus in 32.9-47.8 weeks; no native semaglutide-specific time was supplied.
In plain wordsIn obesity-drug models including semaglutide, pooled drugs reached plateaus in 32.9-47.8 weeks; no semaglutide-specific time was reported.
Peptide
Semaglutide
Outcome
Direction not reportedTime to efficacy plateau across modeled drugs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Reported overall plateau-time range
32.9 to 47.8 weeks
all modeled drugs; not assigned to native drug
Source sentences
Summary
Drugs took 32.9-47.8 weeks to achieve their efficacy plateau, with GLP-1 receptor agonists acting most rapidly.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4064283311
12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obesity-drug models, the GLP-1 group including liraglutide reportedly acted most rapidly; the native estimate, exact rapidity parameter and original reference were unstated.
In plain wordsIn obesity-drug models, the GLP-1 group including liraglutide reportedly acted most rapidly; the exact comparison and native timing were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported rapidity of GLP-1-group modeled efficacy
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Drugs took 32.9-47.8 weeks to achieve their efficacy plateau, with GLP-1 receptor agonists acting most rapidly.
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search of public databases was performed to include randomized placebo-controlled clinical studies on pharmacological treatment of obesity in children and adolescents.
Summary · context
Efficacy characteristics of different weight-loss medications and their influencing factors were characterized by constructing time-course and covariate models, and performing subgroup analyses.
Summary · context
After these adjustments, mean weight reductions at 56 weeks (95% CI) were observed for semaglutide, phentermine-topiramate (PT), sibutramine, probiotics, orlistat, metformin and GLP-1 receptor agonists such as liraglutide, exenatide and dulaglutide
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064283312

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.